Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma

NCT01315873 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

24

Enrollment

OTHER

Sponsor class

Stopped PI left the institution before all data analysis was completed

Conditions

Multiple Myeloma

Interventions

DRUG: Bendamustine
DRUG: Bortezomib

Sponsor

NYU Langone Health

Collaborators

[object Object]